What's with the AFT Pharmaceuticals (ASX:AFP) share price today?

The AFT Pharmaceuticals (ASX: AFP) share price is still in the starting blocks this morning after the company released a trading update.

| More on:
A doctor looks unsure, indicating share price uncertainty for ASX medical companies

Image source: Getty images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The AFT Pharmaceuticals Ltd (ASX: AFP) share price is unmoved in early trading this morning after the company released its latest financial results.

AFT Pharmaceuticals shares finished yesterday's trading up 1.65% to $4.30 per share.

The pharmaceutical drug manufacturer's share price has fallen more than 3% over the past 12 months, so let's take a closer look at the company's trading results for the FY21 period to 31 March.

AFT Pharmaceuticals report

The Australian pharmaceuticals giant released a positive report overall on the company's FY21 performance, despite noting several challenges it has faced this financial year.

The company's highlight was its revenue, which reached a new record of $113.1 million for the 12-month period up to 31 March, up 7% from the $105.6 million in the prior corresponding period.

AFT Pharmaceuticals' profit after tax was down nearly $4 million, decreasing to $7.8 million down from $12.7 million in the prior year, which the company says "benefited from a one-off gain" of $9.8 million related to the orphan drug
Pascomer.

Its Asian market revenue was also weaker, which the company blamed on the region transitioning towards purchasing higher-margin pharmaceutical products. Meanwhile, the company's gross profit grew by 1% to $48.8 million from $48.3 million and its total assets jumped by nearly 20%, as the company sought to protect inventory amounts.

AFT Pharmaceuticals is now targeting an operating profit range of $18 million to $23 million for FY22.

AFT Pharmaceuticals management comments

AFT Pharmaceuticals chair David Flacks said there was a sense of deserved optimism around the company:

The 2021 financial year has been one of the more challenging in AFT's history as business conditions tightened around the world in the wake of the pandemic.

Nevertheless, as we report another year of record revenue and a more than doubling in underlying earnings, we can look back on the year with a sense of achievement.

AFT Pharmaceuticals share price snapshot

Despite its slight losses this past year, the AFT Pharmaceuticals share price remains very close to its 5-year highs, and more than $1 higher than in January 2020.

AFT Pharmaceuticals shares have rocketed by 16% over the past month since the company signed a major US supply deal, but that's against losses of 15% since 2021 began, as well as its broader 12-month decline.

Motley Fool contributor Lucas Radbourne-Pugh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »